Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 2/20 | 0.34 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.30 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.30 |
| ▸ | TERT | O14746 | 1/20 | 0.30 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.30 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338951 | 1.00 | CDC25A (0.34) | CDC25AP2RY10LPAR3TERTUCHL3 | |
| SCHEMBL340042 | 1.00 | CDC25A (0.34) | CDC25AP2RY10LPAR3TERTUCHL3 | |
| SCHEMBL339733 | 0.90 | — | — | |
| SCHEMBL338952 | 0.85 | CDC25A (0.36) | CDC25AP2RY10LPAR3TERTUCHL3 | |
| SCHEMBL339933 | 0.85 | CDC25A (0.36) | CDC25AP2RY10LPAR3TERTUCHL3 | |
| SCHEMBL340043 | 0.85 | CDC25A (0.36) | CDC25AP2RY10LPAR3TERTUCHL3 | |
| SCHEMBL339475 | 0.83 | CDC25A (0.39) | CDC25ALPAR3TERTUCHL3AKT1 | |
| SCHEMBL339696 | 0.83 | FABP3 (0.38) | CDC25ALPAR3AKT1 | |
| SCHEMBL339676 | 0.83 | FABP3 (0.38) | CDC25ALPAR3AKT1 | |
| SCHEMBL339430 | 0.83 | FABP3 (0.38) | CDC25ALPAR3AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097752-B2 | Antiprotozoal ring-substituted phospholipids | MAKSCIENTIFIC, LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20060105998-A1 | Antiprotozoal ring-substiuted phospholipids | MAK SCIENTIFIC CORPORATION (US) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060105998-A1 | Antiprotozoal ring-substiuted phospholipids | PHOSPHO1, PLTP, PLA2G2C | CDC25A 957/4885P2RY10 712/4885LPAR3 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.